I-Mab (IMAB), a biotech company, Thursday reported net loss from continuing operations of $3.15 million or $0.02 per share for the first quarter, lower than $9.42 million or $0.05 per share loss in the same quarter a year ago.
Net loss narrowed to $3.15 million or $0.02 per share from $16.32 million or $0.09 per share loss last year.
The company's lead drug candidate, givastomig in combination with standard of care, nivolumab plus chemotherapy, is being evaluated in a Phase 1b study for the treatment of gastric cancer in dose escalation and dose expansion cohorts. Preliminary data from the dose escalation cohort will be presented at the European Society of Medical Oncology (ESMO) Gastrointestinal Cancers (GI) Congress 2025, being held July 2-5 in Barcelona, Spain.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.